Search research articles
Contact Us
Filters
Showing results (41-50 of 71) with videos related to
Page
of 8
Sort By:
Journal of Cutaneous Medicine and Surgery
|
May 1, 2015
Non-melanoma Skin Cancer in Canada Chapter 3: Management of Actinic Keratoses
Yves Poulin, Charles W Lynde, Kirk Barber, et al.
Journal of Cutaneous Medicine and Surgery
|
December 29, 2011
Topical psoriasis therapy in the age of biologics: evidence-based treatment recommendations
Lorne Albrecht, Marc Bourcier, John Ashkenas, et al.
Journal of Cutaneous Medicine and Surgery
|
May 15, 2018
Canadian Patients' Preferences in Topical Psoriasis Care: Insights From the PROPEL Surveys
Ronald Vender, Melinda J Gooderham, Lyn C Guenther, et al.
Journal of Cutaneous Medicine and Surgery
|
September 28, 2017
Acitretin Use in Dermatology
Lyn C Guenther, Rod Kunynetz, Charles W Lynde, et al.
Stress and Health : Journal of the International Society for the Investigation of Stress
|
November 24, 2018
Cross-sectional survey of workplace stressors associated with physician burnout measured by the Mini-Z and the Maslach Burnout Inventory
Kristine Olson, Christine Sinsky, Seppo T Rinne, et al.
Acta Dermato-Venereologica
|
September 19, 2022
Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3
Alexander Egeberg, Lars Erik Kristensen, Ronald Vender, et al.
Dermatology and Therapy
|
December 9, 2017
Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies
David Pariser, Ellen Frankel, Joel Schlessinger, et al.
Skin Therapy Letter
|
January 25, 2024
Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients
Tuba Bukhari, Mariya Markovina, Abrahim Abduelmula, et al.
Dermatology and Therapy
|
February 9, 2024
Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)
Melinda Gooderham, Ronald Vender, Jeffrey Crowley, et al.
Frontiers in Medicine
|
August 27, 2021
A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab
Feras M Ghazawi, Farhan Mahmood, Leon Kircik, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 71) with videos related to
Sort By:
Page
of 8
Journal of Cutaneous Medicine and Surgery
|
May 1, 2015
Non-melanoma Skin Cancer in Canada Chapter 3: Management of Actinic Keratoses
Yves Poulin, Charles W Lynde, Kirk Barber, et al.
Journal of Cutaneous Medicine and Surgery
|
December 29, 2011
Topical psoriasis therapy in the age of biologics: evidence-based treatment recommendations
Lorne Albrecht, Marc Bourcier, John Ashkenas, et al.
Journal of Cutaneous Medicine and Surgery
|
May 15, 2018
Canadian Patients' Preferences in Topical Psoriasis Care: Insights From the PROPEL Surveys
Ronald Vender, Melinda J Gooderham, Lyn C Guenther, et al.
Journal of Cutaneous Medicine and Surgery
|
September 28, 2017
Acitretin Use in Dermatology
Lyn C Guenther, Rod Kunynetz, Charles W Lynde, et al.
Stress and Health : Journal of the International Society for the Investigation of Stress
|
November 24, 2018
Cross-sectional survey of workplace stressors associated with physician burnout measured by the Mini-Z and the Maslach Burnout Inventory
Kristine Olson, Christine Sinsky, Seppo T Rinne, et al.
Acta Dermato-Venereologica
|
September 19, 2022
Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3
Alexander Egeberg, Lars Erik Kristensen, Ronald Vender, et al.
Dermatology and Therapy
|
December 9, 2017
Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies
David Pariser, Ellen Frankel, Joel Schlessinger, et al.
Skin Therapy Letter
|
January 25, 2024
Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients
Tuba Bukhari, Mariya Markovina, Abrahim Abduelmula, et al.
Dermatology and Therapy
|
February 9, 2024
Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)
Melinda Gooderham, Ronald Vender, Jeffrey Crowley, et al.
Frontiers in Medicine
|
August 27, 2021
A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab
Feras M Ghazawi, Farhan Mahmood, Leon Kircik, et al.
Page
of 8